Vanguard Capital Management
CRVS icon

Vanguard Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Vanguard Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.2M Buy
3,292,710
+58,172
+2% +$807K ﹤0.01% 1958
2026
Q1 		$47.3M Buy
+3,234,538
New +$51.6M ﹤0.01% 1882

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Vanguard Capital Management's CRVS Position: Q2 2026 in Review

Vanguard Capital Management increased its Corvus Pharmaceuticals (CRVS) stake by 1.8% in Q2 2026, buying an estimated $807K and bringing the position to 3,292,710 shares worth $49.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1958.

Vanguard Capital Management first reported a position in CRVS in Q1 2026 and has held it in 2 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Vanguard Capital Management held 3,292,710 shares of Corvus Pharmaceuticals worth $49.2M as of Q2 2026.
  • Vanguard Capital Management bought 58,172 Corvus Pharmaceuticals shares in Q2 2026, an estimated $807K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1958 holding.
  • Vanguard Capital Management first reported a position in Corvus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.